PureTech Health plc announced that the peer‑reviewed results of its Phase 2b ELEVATE study for deupirfenidone have been published in the American Journal of Respiratory and Critical Care Medicine. The publication confirms that the drug met its primary endpoint of slowing the decline in forced vital capacity, with a statistically significant difference versus placebo and a safety profile comparable to the standard‑of‑care antifibrotic pirfenidone.
The trial demonstrated a 30‑percent reduction in the annual rate of lung function decline compared with placebo, and the safety data showed no new or unexpected adverse events. Because deupirfenidone is a deuterated form of pirfenidone, the study’s head‑to‑head comparison provides the strongest evidence yet that the modified molecule can offer improved tolerability while maintaining efficacy, a key factor in the drug’s potential to become a preferred treatment option.
These results reinforce PureTech’s 505(b)(2) regulatory strategy, which leverages the existing safety and efficacy data of pirfenidone to streamline the approval process for the deuterated analogue. The publication also bolsters the company’s hub‑and‑spoke model, as the Celea Therapeutics spoke that focuses on deupirfenidone is positioned to attract external investors and secure the financing needed to launch the Phase 3 SURPASS‑IPF trial. The data will inform the design of the upcoming head‑to‑head study against pirfenidone, a critical step toward demonstrating superiority and securing market access.
PureTech’s management highlighted the significance of the study, noting that the ELEVATE trial “provides a rare opportunity to evaluate an investigational therapy for IPF directly alongside a current standard‑of‑care treatment within a randomized controlled trial.” The company’s leadership views the publication as a pivotal milestone that will accelerate the asset’s path to commercialization and enhance its attractiveness to potential partners or acquirers.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.